Taken together, these limitations highlight the necessity of stratifying IBD patients by smoking status when considering GPR15-targeted interventions and underscore the importance of future studies employing chronic or humanized models to validate and extend these findings. This evidence concerns the gene GPR15 and inflammatory bowel disease.